Published in Oncol Rep on March 01, 2006
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer (2007) 2.09
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol (2015) 1.63
The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.26
Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis (2008) 1.18
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer (2009) 1.08
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 1.07
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech (2013) 1.01
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference. Hepatology (2008) 0.96
Recent advances in the regulation of cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol (2010) 0.95
Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects. Int J Mol Sci (2013) 0.91
Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. Transl Gastrointest Cancer (2012) 0.91
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol (2013) 0.90
Vascular factors, angiogenesis and biliary tract disease. Curr Opin Gastroenterol (2010) 0.88
Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. Oncologist (2015) 0.83
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs (2012) 0.81
Expression of angiopoietin-1, 2 and 4 and Tie-1 and 2 in gastrointestinal stromal tumor, leiomyoma and schwannoma. World J Gastroenterol (2007) 0.80
Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma. PLoS One (2014) 0.79
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol (2015) 0.78
Angiopoietin-1 targeted RNA interference suppresses angiogenesis and tumor growth of esophageal cancer. World J Gastroenterol (2008) 0.78
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Sci Rep (2016) 0.78
Cholangiocarcinoma: estrogen-induced autocrine effects of VEGF on cell proliferation. Dig Liver Dis (2008) 0.77
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs (2015) 0.75
Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. PLoS One (2015) 0.75
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. Int J Mol Sci (2017) 0.75
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Lett (2016) 0.75
Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell (2011) 4.02
CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest (2010) 3.60
Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem (2003) 3.41
A Bayesian missing value estimation method for gene expression profile data. Bioinformatics (2003) 3.19
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J (2014) 2.76
Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J Biol Chem (2003) 2.66
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology (2010) 2.48
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol (2013) 2.45
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Cronkhite-Canada syndrome containing colon cancer and serrated adenoma lesions. Digestion (2004) 2.19
A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J (2013) 2.19
Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res (2007) 2.19
Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol (2011) 2.18
Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg (2013) 2.17
A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes. J Surg Oncol (2006) 2.16
Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial. Lancet (2013) 2.14
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A (2009) 2.11
Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res (2011) 2.11
Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol (2004) 2.10
High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg (2005) 2.04
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J (2015) 2.03
Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol (2007) 2.02
Laparoscopy-assisted hybrid left-side donor hepatectomy. World J Surg (2013) 2.02
The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun (2011) 2.02
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol (2010) 2.00
Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci (2012) 1.98
TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology (2013) 1.94
Implications of nectin-like molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization in epithelial cells. J Biol Chem (2003) 1.86
In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol (2002) 1.86
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum (2002) 1.79
Biology of hepatocellular carcinoma. Ann Surg Oncol (2008) 1.78
Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol (2004) 1.78
Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial (2005) 1.78
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer (2007) 1.77
Modeling of the human middle ear using the finite-element method. J Acoust Soc Am (2002) 1.76
Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res (2004) 1.75
Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery (2007) 1.75
Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res (2006) 1.75
Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia: OLIVE registry, a prospective, multicenter study in Japan with 12-month follow-up. Circ Cardiovasc Interv (2013) 1.70
Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Oncol (2007) 1.67
Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl (2012) 1.64
Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med (2003) 1.61
LC3, an autophagosome marker, is highly expressed in gastrointestinal cancers. Int J Oncol (2008) 1.61
Donor complications associated with living donor liver transplantation in Japan. Transplantation (2009) 1.60
Direct binding of cell polarity protein PAR-3 to cell-cell adhesion molecule nectin at neuroepithelial cells of developing mouse. J Biol Chem (2003) 1.60
Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol (2005) 1.60
Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy. Surgery (2009) 1.60
Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res (2004) 1.59
Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J (2013) 1.57
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation (2013) 1.55
Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma. Ann Surg Oncol (2004) 1.54
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer (2002) 1.54
Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res (2009) 1.52
Risk factors for alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan. Liver Transpl (2014) 1.52